Lupin to focus on cancer drugs in Japan
The new focus area can be expected to help the company meet its target of touching sales worth US$ 500 million in the next five years in the Japanese market.
New Delhi, October 14, 2012: The drug firm Lupin has identified cancer drugs as its new focus area in the Japanese market as patents worth US$ 2 billion are expected to expire in this category over the next five years. The company has established its presence in the Japanese market through two wholly -owned subsidiaries, Kyowa Pharmaceutical Industry and I'rom Pharmaceuticals.
Lupin has been able to create a portfolio of 7-8 oncology products in the Japanese market with a mix of in-licensing and co-development. So far, Lupin has presence in both oral and injectable products development and manufacturing infrastructure in Japan.
The company will be marketing its products through I'rom DPC team to target about 400 cancer hospitals in Japan in addition to setting up a dedicated oncology product packaging facility in-house in Sanda.
The company has a target to double its sales in the Japanese market to US$ 500 million over the next five years. According to industry estimates, the Japanese market will expand in next 3-5 years, as there are significant patent expiries for products worth US$ 10 billion.
It is believed that the generic drug penetration in Japan will go up to 35 per cent by the end of 2016. Currently, there are close to 20-30 generic drug companies operating in the Japanese market.